The board of directors of biopharmaceutical company Pfizer Inc (NYSE:PFE) declared the company's 321st consecutive dividend of USD0.36 of its common stock for the first quarter 2019, it reported on Friday.
This new dividend marks a growth of approximately 6% from the prior dividend of USD0.34 per share of its common stock.
Shareholders of record at the close of business as of 1 February 2019 will receive the dividend on 1 March 2019,
Additionally, the board of directors has launched a new USD10bn share repurchase programme,which is in addition to the USD4.9bn remaining under its current authorisation.
Acerus and Aytu Bioscience to Co-promote Natesto in the United States
Amgen reports financial results for Q2 2019
Pfizer to integrate Upjohn with Mylan to establish new global pharmaceutical company
Neurocrine Biosciences reports half-year ended 30 June 2019 financial results
Thermo Fisher Scientific reports financial results for Q2 2019
Veloxis Pharmaceuticals revises 2019 outlook
NANOBIOTIX collects revenues of EUR31.9,000 for Q2 2019
Seattle Genetics incurs net loss of USD79.2m in Q2 2019
Baxter's board announces USD0.22 per share dividend pay order
Johnson & Johnson declares dividend of USD0.95 per share for Q3 2019
Sun Pharma Launches Ezallor Sprinkle in the US for People Who Have Difficulty Swallowing
PanTheryx Aims to End Diarrheal Disease in Cambodia
CCA Industries Inc swings to income of USD349,320 for Q2 2019
Oncimmune Holdings signs commercial collaboration with R-Pharm JSC